Challenges and therapeutic opportunities in the dMMR/MSI-H colorectal cancer landscape
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Mulet Margalef, Núria
- dc.contributor.author Linares Aceituno, Jenniffer Lissethe
- dc.contributor.author Badia-Ramentol, Jordi
- dc.contributor.author Jimeno, Mireya
- dc.contributor.author Sanz Monte, Carolina
- dc.contributor.author Manzano Mozo, José Luis
- dc.contributor.author Calon, Alexandre
- dc.date.accessioned 2024-04-17T06:20:28Z
- dc.date.available 2024-04-17T06:20:28Z
- dc.date.issued 2023
- dc.description.abstract About 5 to 15% of all colorectal cancers harbor mismatch repair deficient/microsatellite instability–high status (dMMR/MSI-H) that associates with high tumor mutation burden and increased immunogenicity. As a result, and in contrast to other colorectal cancer phenotypes, a significant subset of dMMR/MSI-H cancer patients strongly benefit from immunotherapy. Yet, a large proportion of these tumors remain unresponsive to any immuno-modulating treatment. For this reason, current efforts are focused on the characterization of resistance mechanisms and the identification of predictive biomarkers to guide therapeutic decision-making. Here, we provide an overview on the new advances related to the diagnosis and definition of dMMR/MSI-H status and focus on the distinct clinical, functional, and molecular cues that associate with dMMR/MSI-H colorectal cancer. We review the development of novel predictive factors of response or resistance to immunotherapy and their potential application in the clinical setting. Finally, we discuss current and emerging strategies applied to the treatment of localized and metastatic dMMR/MSI-H colorectal tumors in the neoadjuvant and adjuvant setting.
- dc.format.mimetype application/pdf
- dc.identifier.citation Mulet-Margalef N, Linares J, Badia-Ramentol J, Jimeno M, Sanz Monte C, Manzano Mozo JL, et al. Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape. Cancers (Basel). 2023 Feb 6;15(4):1022. DOI: 10.3390/cancers15041022
- dc.identifier.doi http://dx.doi.org/10.3390/cancers15041022
- dc.identifier.issn 2072-6694
- dc.identifier.uri http://hdl.handle.net/10230/59800
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Cancers (Basel). 2023 Feb 6;15(4):1022
- dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Colorectal cancer
- dc.subject.keyword Mismatch repair
- dc.subject.keyword Microsatellite instability
- dc.subject.keyword Immunotherapy
- dc.title Challenges and therapeutic opportunities in the dMMR/MSI-H colorectal cancer landscape
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion